Relapsed or Refractory Peripheral T Cell Lymphoma
8 clinical trials · Condition
◉ Watch Relapsed or Refractory Peripheral T Cell Lymphoma
| Record | Firm | Date |
|---|---|---|
| A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma (NCT04108325) | Shanghai YingLi Pharmaceutical Co. Ltd. | 2020-03-30 |
| Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (NCT04329130) | Sun Yat-sen University | 2020-03-27 |
| Pralatrexate for Relapsed or Refractory Peripheral T-cell Lymphoma (NCT03356678) | Samsung Medical Center | 2016-09-23 |
| Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy (NCT02464228) | Kura Oncology, Inc. | 2016-02-25 |
Track Relapsed or Refractory Peripheral T Cell Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.